PMID: 15226620Jul 1, 2004Paper

Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Motohiko ChachinHisashi Satoh

Abstract

Telmisartan (Micardis) is a potent, long-lasting, nonpeptide angiotensin II type-1 (AT(1)) receptor blocker (ARB) that is indicated for the treatment of essential hypertension. In receptor binding studies, telmisartan showed a high affinity and selectivity for the human AT(1) receptors compared with AT(2) receptors and a slower dissociation rate from the human AT(1) receptor than those of ARBs. In isolated aorta rings, telmisartan was shown to be an insurmountable antagonist of AII-induced contractions. The inhibitory effects of telmisartan on AII-induced contraction persisted even after wash-out procedures. In animal models such as spontaneous hypertension rats and renovascular hypertensive rats, telmisartan produced the consistent reduction of blood pressure. Furthermore, there were no rebound phenomenon and no tolerance to the drug developed in the repeated oral administration. Telmisartan has a longer terminal elimination half-life (about 24 h) than the other ARBs. In patients with mild-moderate hypertension, trough/peak ratios for telmisartan were above 80%. In Japanese patients with mild-moderate hypertension, telmisartan produced a significant reduction in blood pressure (effective rate: 76.0%) with a good safety profile...Continue Reading

References

Mar 25, 1991·European Journal of Pharmacology·M Entzeroth, S Hadamovsky
Jul 15, 1990·The American Journal of Cardiology·R J GoldbergJ E Dalen
Apr 1, 1989·Stroke; a Journal of Cerebral Circulation·J R MarlerM A Foulkes
Jul 29, 1988·The American Journal of Medicine·M H Smolensky, G E D'Alonzo
Jan 1, 1997·European Journal of Clinical Pharmacology·G FleschP Lloyd
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Jun 15, 2000·Journal of Human Hypertension·Z H Israili
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Mar 7, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·W WienenC Audeval-Gerard
Dec 25, 2002·Japanese Journal of Pharmacology·Shinji Takai, Mizuo Miyazaki
Jan 25, 2003·Journal of Hypertension·Albert Ferro
Feb 7, 2003·Fundamental & Clinical Pharmacology·G VauquelinP M L Vanderheyden
Apr 11, 2012·Journal of Veterinary Pharmacology and Therapeutics·T EbnerJ Elliott

❮ Previous
Next ❯

Citations

Nov 13, 2008·Journal of Oleo Science·Noriko MiyazawaShoji Ohga
Aug 19, 2007·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Ichiro TsunenariYoshiharu Horie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.